Stock price quadrupled in 3 years, market value surpasses leading Illumina! This "cancer early screening" company is highly favored by Wall Street.
```
A company specializing in cancer recurrence detection is reshaping the landscape of the blood tumor testing market.
Headquartered in Austin, Texas, Natera has achieved a near-monopoly in the field of minimal residual disease (MRD) detection. Its stock price has quadrupled in three years, reaching a market capitalization of about $31